I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine

- Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab Biopharma (I-Mab). - I-Mab receives exclusive development and commercialization rights to HyLeukin in Mainland China, Taiwan, Hong Kong...